Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Baruch D. Kuppermann, MD, PhD, discusses positive data from real-world studies assessing intravitreal implants for diabetic macular edema.
According to Kuppermann, Steinert Endowed Professor and chair of the department of ophthalmology and visual sciences at the University of California, Irvine, patients in the ERLYDEX study with suboptimal responses to anti-VEGF therapy who were switched to Ozurdex (dexamethasone intravitreal implant, AbbVie) “showed benefit compared with those that were maintained on anti-VEGF both in terms of